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Abstract
Background: Missing clinical outcome data are a common occurrence in longitudinal studies. Data quality in
clinical audit is a particular cause for concern. The relationship between departmental levels of missing clinical
outcome data and care quality is not known. We hypothesise that completeness of key outcome data in a national
audit predicts departmental performance.
Methods: The National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis (NCAREIA) collected data on
care of patients with suspected rheumatoid arthritis (RA) from early 2014 to late 2015. This observational cohort
study collected data on patient demographics, departmental variables, service quality measures including time to
treatment, and the key RA clinical outcome measure, disease activity at baseline, and 3 months follow-up. A mixed
effects model was conducted to identify departments with high/low proportions of missing baseline disease
activity data with the results plotted on a caterpillar graph. A mixed effects model was conducted to assess if
missing baseline disease activity predicted prompt treatment.
Results: Six thousand two hundred five patients with complete treatment time data and a diagnosis of RA were
recruited from 136 departments. 34.3% had missing disease activity at baseline. Mixed effects modelling identified
13 departments with high levels of missing disease activity, with a cluster observed in the Northwest of England.
Missing baseline disease activity was associated with not commencing treatment promptly in an adjusted mix
effects model, odds ratio 0.50 (95% CI 0.41 to 0.61, p < 0.0001).
Conclusions: We have shown that poor engagement in a national audit program correlates with the quality of
care provided. Our findings support the use of data completeness as an additional service quality indicator.
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Background
National clinical audits (NCAs) are a key lever to im-
prove quality of care and limit unwarranted variation.
The National Lung Cancer Audit and the Sentinel
Stroke National Audit Programme (SSNAP) are exam-
ples of how care can be improved through national audit
[1, 2]. In order to assess care quality, NCAs rely on met-
rics that can be split into two distinct groups:
1. Process measures. Typically a guideline
recommendation that applies a threshold of quality
to a particular aspect of care delivery [3], for
example, time to surgery in the hip fracture
database [4] or time to thrombolysis in SSNAP [1];
2. Clinical outcome measures. Quantifiable changes in
health status as a result of an intervention [5], for
example, blood glucose levels in the National
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Diabetes Audit [6] or disease activity scores in the
National Early inflammatory arthritis audit [7].
Missing or incomplete data are a common finding in
any longitudinal dataset, particularly in NCAs that, by
and large, rely on clinician time and goodwill for data
collection. Process measures tend to have higher data
completeness as they are simple to collect from elec-
tronic health records. Clinical outcomes measures are
more challenging to collect, often requiring blood tests,
specific examination findings, or calculation of scores
derived from multiple metrics, and so are more likely to
have lower data completeness.
Rheumatoid arthritis (RA) is primarily managed in the
outpatient setting with multiple follow-up appointments.
This increases the likelihood of missing outcome data.
Despite this, patterns of missing data are frequently not
reported in RA observational studies [8].
It is not known if departments with higher levels of in-
complete clinical outcome data are delivering lower
quality care. We hypothesised that the completeness of
key outcome data in a national clinical audit could pre-
dict departmental performance.
The objectives of this study are to utilise an NCA
dataset to:
1. Describe departmental level variations in outcome
data quality across the National Health Service
(NHS) in England and Wales;
2. Investigate if completeness of a clinical outcome
measure correlates with process measures.
Methods
Sample
In 2014, the Healthcare Quality Improvement Partner-
ship (HQIP)-commissioned National Clinical Audit for
Rheumatoid and Early Inflammatory Arthritis (NCAR-
EIA) was launched. This NCA sought to assess the qual-
ity of early inflammatory arthritis (EIA) care delivered
and clinical outcomes. All rheumatology departments
across England and Wales were mandated to participate.
Data were collected at departmental level from February
2014 to October 2015 via an online portal. Data were
only reported from departments that contributed > 5
participants to each analysis, in line with the audit’s low
number reporting policy to maintain anonymity.
Patients aged > 16 years referred to a rheumatology de-
partment with symptoms consistent with EIA were eli-
gible for inclusion, but the analyses in this study only
required data for patients with symptoms consistent
with RA. This was defined as any patient with a new on-
set of inflammatory arthritis, longer than 6 weeks dur-
ation, and either a positive rheumatoid factor (RF), anti-
cyclic citrullinated protein (anti-CCP) antibody, or a
swollen joint count of five or more. Data were collected
at baseline appointment and at a 3-month follow-up.
Data
Patient demographic variables collected at baseline in-
cluded age, gender, smoking status, ethnicity, work sta-
tus, and the first three characters of postcode.
A proxy rank of the index of multiple deprivation
(IMD) was calculated from partial patient postcodes by
identifying all lower super output areas (LSOAs) covered
by each postcode. The corresponding IMD scores were
then averaged for each patient, allowing calculation of
an estimation of deprivation across the cohort.
Departmental variables collected included staffing
levels, catchment population, and dedicated EIA clinic
presence. The process measures collected included (1)
number of days from primary care review to referral to
rheumatology care (referral time), (2) number of days
from referral to rheumatology review (review time), and
(3) number of days from referral to treatment com-
mencement (treatment time).
Referral and review times were calculated at baseline
appointment for all patients. Data from the 3months
follow-up was used to calculate treatment time for those
who were not commenced on treatment at their baseline
appointment. The process measures were collected in
accordance with national guidelines for suspected in-
flammatory arthritis care [9].
Clinical outcome measures collected at baseline and
3 months follow-up included tender and swollen joint
counts, patient-reported visual analogue scale of symp-
tom severity, blood erythrocyte sedimentation rate
(ESR), and C-reactive protein (CRP) levels.
The clinical outcome measures were utilised to calcu-
late disease activity scores (DAS28), a multi-component
score of disease activity in RA [10]. DAS28 is a key clin-
ical outcome measure, utilised widely across rheumatol-
ogy services to assess response to therapy. The score is
calculated from tender and swollen joint counts, a pa-
tient assessment of overall symptom severity on 100-mm
visual analogue scales, and blood inflammatory marker
levels (ESR or CRP), with higher scores indicating
greater disease severity. If patients had both an ESR and
CRP level, the ESR level was preferentially used to calcu-
late their DAS28.
Statistical analysis
Characterising departmental variation in data completeness
A mixed effects model was conducted to identify depart-
ments with high or low proportions of missing baseline
DAS28 data, adjusting for case mix. Departments who
had recruited more than five patients were included in
the model.
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Missing baseline DAS28 data was the outcome variable
with patient-level variables included as fixed effects (age,
gender, work status, area level social deprivation, smok-
ing status; ethnicity, symptom duration, antibody status)
and department included as a random effect. The ran-
dom effect captures the difference between the depart-
mental proportion of incomplete data and the overall
proportion of incomplete data in the sample. The esti-
mated proportions from the model are empirical Bayes
estimates, which, following the logic of Bayesian infer-
ence, is a ‘shrinkage’ estimator exploiting additional in-
formation that typically moves the estimate towards the
overall proportion for the sample. Shrinkage estimates
have several desirable properties, including greater preci-
sion and accounting for larger random variation ob-
served at smaller centres [11].
The observed and model-estimated departmental pro-
portions of missing baseline DAS28 data were plotted
on a caterpillar graph, with 95% confidence intervals
(CI) for the predicted values, to allow a ranking of de-
partments by proportions of missing data.
A department was considered to have a high propor-
tion of missing data if their predicted 95% CI lower
bound was greater than the overall mean. Similarly, a de-
partment was considered to have a low proportion of
missing data if their predicted 95% CI upper bound was
less than the sample mean. The locations of the depart-
ments with high and low levels of missing data were
mapped using the grmap software package [12] in Stata
15 to give a national representation.
Missing clinical outcome data as a predictor of service
quality
To test the hypothesis that completeness of key outcome
data is a usable surrogate for departmental performance,
mixed effects modelling was performed with the depart-
ment providing care included as a random effect. Incom-
plete baseline DAS28 was the independent variable, with
treatment time as the dependent variable.
Treatment time was used in preference to referral
time, as the latter is an assessment of primary care ra-
ther than rheumatology department performance.
Shorter treatment times are considered a key marker of
service quality in early RA care [13]. Analyses from the
latest EIA NCA annual report show that shorter treat-
ment times correspond to better clinical outcomes [14].
Treatment time was converted to a binary variable in-
dicating whether treatment commenced within 90 days
of referral to rheumatology specialist care. The model
was first performed unadjusted for covariates with
reporting of odds ratios, p values, and 95% CI for the
primary hypothesis test.
The model was repeated adjusting for patient level co-
variates selected a priori: age, gender, work status, area
level social deprivation, smoking status, ethnicity, symp-
tom duration, rheumatoid, and anti-CCP antibody sta-
tus. The adjusted model was then repeated with further
adjustment for departmental characteristics selected a
priori: specialist nurse and consultant staffing levels per
head of catchment population; presence or absence of a
dedicated EIA clinic, and departmental proportions of
missing DAS28 data. Model fit was assessed by compar-
ing area under the curve values (AUC) for observed and
predicted performance data.
As analyses were exploratory in nature, no correction
for multiple hypothesis testing was performed. All ana-
lyses were conducted using Stata 15 statistical software
package.
Results
A total of 6205 patients with a diagnosis of RA and
complete treatment time data were recruited from 136
departments across England and Wales. Table 1 details
baseline and demographic characteristics, process mea-
sures, clinical outcome measures, and proportions of
missing data. There were substantial proportions of in-
complete DAS28 data at baseline with 2130/6205
(34.3%) missing data.
Table 2 provides further detail on the missing compo-
nents of baseline DAS28.
There were demographic differences between patients
with complete and incomplete baseline DAS28 data (see
Table 3). Those with incomplete baseline DAS28 data
were younger, less likely to smoke, more likely to be in
paid work, less likely to be RF or anti-CCP antibody
positive, and had longer symptom duration prior to
presentation. Amongst those with incomplete baseline
DAS28, 50.3% were commenced on treatment within 90
days, compared to 65.3% in those with complete DAS28
data.
Characterising departmental variations in data
completeness
Mixed effects modelling to identify departments with
outlier levels of missing DAS28 data was conducted. The
model identified 13 departments with high levels of
missing data and 7 with low levels. The case-mix ad-
justed departmental effects are plotted in Fig. 1a. The
analysis demonstrates wide variation across departments.
The model has accounted for sample size and case
mix, shrinking estimates towards the grand mean as a
result of them being empirical Bayes estimates, with the
level of shrinkage dependent on the number of observa-
tions for each department.
The locations of outlier departments were mapped,
displayed in Fig. 1b, with red markers indicating depart-
ments with high outlier levels of missing baseline DAS28
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data. Geographic clustering of high outlier departments
is visible in the North West region.
Missing clinical outcome data as a predictor of service
quality
Logistic regression models were constructed to assess if
missing baseline DAS28 data predicted timely treatment
commencement (within 90 days of referral). In mixed ef-
fects models, missing baseline DAS28 was associated
with not commencing treatment promptly, with odds ra-
tios of 0.48 (95% CI 0.42 to 0.54, p < 0.0001) in the un-
adjusted model and 0.50 (95% CI 0.41 to 0.61, p <
0.0001) in the model adjusted for patient level factors.
The association was maintained after adjustment for de-
partment level factors, odds ratio 0.50 (95% CI 0.41 to
0.61, p < 0.0001). A comparison of the models is pre-
sented in Fig. 2.
Staffing levels had a substantial impact on the esti-
mates with higher nursing levels and, paradoxically,
lower consultant levels associating with a greater chance
for prompt treatment initiation.
Sensitivity analyses were conducted to investigate the
impact of staffing levels on data completeness. Mixed ef-
fects modelling with nurse and consultant densities as a
predictor of missing baseline DAS28 gave odds ratios of
1.11 (95% CI 0.91 to 1.34) and 0.97 (95% CI 0.76 to
1.25) respectively, suggesting staffing levels were not in-
dependent predictors of missing DAS28.
Discussion
These data from an outpatient-based NCA identify a
strong relationship between clinical outcome data com-
pleteness and care quality, maintained after extensive ad-
justment for patient and department level factors. The
relationship suggests missing baseline disease activity
data are an indirect indicator for service quality in RA
care.
By using a mixed effects model in our analyses, we
have been able to account for case mix and volume of
activity in our estimates of data quality. As a result, we
have robustly identified departments that substantially
deviate from expected data return levels, accounting for
confounding due to case-mix and potential small sample
effects [11].
There was broad variation in departmental complete-
ness of baseline disease activity data. High levels of in-
complete clinical outcome measures detrimentally affect
the face validity of NCA findings. Process measures,
such as treatment time in NCAREIA, tend to have lower
Table 1 Baseline characteristics and quality of care received, including levels of missing data
N = 6205 Number missing (%)
Age, mean (SD) 58.2 (15.2) 37 (0.5)
Female, % 63.7 37 (0.5)
IMD rank, median (Q1, Q3) 639 (300 to 1021) 683 (11.0)
White European, % 90.8 1423 (23.0)
Current smoker, % 22.3 1170 (18.6)
Full time paid employment, % 39.3 1236 (20.0)
Seropositive, % 77.8 1594 (25.7)
Baseline DAS28, mean (SD) 5.1 (1.4) 2130 (34.3)
Follow-up DAS28, mean (SD) 3.5 (1.5) 3864 (62.3)
Change in DAS28, mean (SD) 1.7 (1.6) 4222 (68.0)
Rheumatology Departments 136 0
Symptom duration in days, median (Q1, Q3) 103 (53 to 223) 59 (1.0)
Referral within 3 days, % 17.0 0
Review within 21 days, % 37.2 0
Treatment within 90 days, % 60.1 0
SD standard deviation, IMD index of multiple deprivation, DAS28 disease activity score 28
Patients who were positive for rheumatoid factor and/or anti-citrullinated c-peptide were considered seropositive
Table 2 DAS28 missing data table with components
breakdown
N = 6205 Number missing at baseline (%)
Tender joint count 370 (6.0%)
Swollen joint count 372 (6.0%)
Patient global VAS 1012 (16.3%)
ESR 2075 (33.4%)
CRP 1625 (26.2%)
ESR and CRP 472 (7.6%)
VAS visual analogue scale, ESR erythrocyte sedimentation rate, CRP
C-reactive protein
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levels of missing data, good precision, and a lower risk
of bias. Despite this, clinicians may place greater em-
phasis on clinical outcome measures even when the data
are incomplete [15]. This is perhaps explained by
clinician familiarity with the clinical outcome measures
from trials within the field, in contrast to the paucity of
studies that evaluate process measures in healthcare.
Table 3 Baseline characteristics, disease activity, and quality of care received stratified by complete and incomplete baseline DAS28
data
Complete baseline DAS28 data Incomplete baseline DAS28 data p values
(N = 4075) (N = 2130)
Age, mean (SD) 59.0 (14.8) 56.6 (15.8) < 0.0001
Female 64.1% 62.8% 0.3
IMD rank, median (Q1, Q3) 638 (306, 1021) 639 (270, 1021) 0.3
White European 90.6% 91.3% 0.5
Current Smoker 23.5% 19.8% 0.003
Full time paid employment 36.8% 40.7% 0.008
Seropositive 83.0% 65.3% < 0.0001
DAS28 at follow-up, mean (SD) 3.5 (1.5) 3.6 (1.5) 0.3
Symptom duration in days, median (Q1, Q3) 98 (52, 208) 114 (56, 256) 0.0001
Referral letter states EIA 91.2% 88.8% 0.002
Referral within 3 days 16.5% 18.0% 0.1
Review within 21 days 36.9% 36.7% 0.6
Treatment within 90 days 65.3% 50.3% < 0.0001
SD standard deviation, IMD index of multiple deprivation, DAS28 disease activity score 28, EIA early inflammatory arthritis
Patients who were positive for RF and/or anti-CCP were considered seropositive
Fig. 1 Caterpillar plot and map characterising departmental variations in data completeness. a The grey markers are the observed departmental
proportions of missing baseline DAS28 data. The blue markers are the predicted departmental proportions after adjustment for case mix and
applying a shrinkage to account for the small overall sample size, with 95% confidence intervals in red. The black horizontal line represents the
overall sample mean. The further to the right along the x-axis indicates worse performance by a department, i.e. a greater proportion of missing
DAS28 data. b Locations of outlier departments mapped across England and Wales. Red markers represent departments with high outlier levels
of missing baseline DAS-28. Green markers represent low outliers
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There appeared to be a cluster of departments with
high degrees of missing data in the North West region.
The purpose of mapping performance was to seek evi-
dence for regional clustering. The mapping presented
suggests that clustering may be present, and this war-
rants further investigation. Clinical departments often
share networks within their locality, with common train-
ing programs and regional education events. If regional
trends in performance are apparent, and genuine, these
provide an opportunity for a collective service improve-
ment program.
There were striking differences between patients with
complete and incomplete DAS28 data, suggesting the
data are missing not at random. The drivers behind
missing DAS28 data warrant further discussion. Partici-
pation in NCAREIA was mandatory, but still relied on
clinician goodwill for data entry. It is likely that clini-
cians put greater emphasis on collecting data for patients
with ‘typical’ or severe symptoms of RA. This is sup-
ported by the higher proportion of seropositive patients
in those with complete DAS28 data.
Missing data are a challenge in any observational data-
set, particularly in NCAs that rely on clinician goodwill
for case ascertainment and data collection. HQIP, re-
sponsible for the commissioning of NCA activity within
the NHS in England, recommend that missing data can
be reduced, by rationalising of data collection, so only
the most important information is sought; mitigated, via
linkage to alternative data sources to ‘backfill’ data gaps;
and imputed, utilising statistical modelling [16].
Rationalisation of data collection is a key component
in the design of an NCA. A balance must be struck be-
tween the desire to collect as much information as pos-
sible and the challenge for clinicians tasked with
recruiting patients while running busy services. Data
linkage to fill in data gaps, for example using the clinical
practice research datalink of primary care data to attain
patient demographic details, is in theory possible but in
practice not feasible as this will require additional ap-
provals to access and link alternative data sources.
Therefore, data imputation is often required to allow
analysis without omitting individuals with incomplete re-
cords, which potentially introduces selection bias. A
widely used principled approach to missing data is mul-
tiple imputation, which estimates a range plausible miss-
ing values [17]. It is now widely used in the published
literature and has been utilised in NCAREIA analyses
[18].
The impact of missing clinical outcomes in NCAs is
often only partially addressed [19, 20], increasing the
likelihood of biased findings. All NCAs should have a ro-
bust missing data plan in keeping with HQIP
Fig. 2 Mixed effects modelling of missing baseline DAS-28 data as a predictor of prompt treatment commencement. Model 1 (N = 6205) is
unadjusted. Model 2 (N = 2979) is adjusted for patient covariates: age, gender, work status, socioeconomic position, smoking status, ethnicity,
symptom duration, rheumatoid, and anti-CCP antibody status. Model 3 (N = 2943) is adjusted for patient covariates and the following
departmental characteristics: specialist nurse and consultant staffing levels per head of catchment population, presence or absence of a dedicated
EIA clinic, and departmental proportions of missing DAS28 data. Department was included as a random intercept in all three models
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recommendations. The findings presented here suggest
that in circumstances where missing clinical outcome
data cannot be avoided, it may have utility as a surrogate
for service performance.
Work on other NCAs has highlighted non-
participation as a predictor for departments that deliver
lower quality care [21], but this study is the first to high-
light the utility of partial participation, submitting in-
complete data, as a predictor capable of identifying
departments with outlier performance.
The strengths of this study are that it was conducted
using a large dataset with missing data characteristics
similar to other NCAs. Analyses were extensively ad-
justed for patient and departmental covariates, with de-
partment included as a random effect in the model to
account for the hierarchy of the dataset. The findings
identified that (1) the degree of missing clinical outcome
data varies broadly across departments, allowing the de-
tection of outliers, and (2) missing clinical outcome data
associates with service quality. The combination of these
findings supports the utility of missing outcome data as
a usable proxy for service quality.
These findings do not in themselves support the util-
isation of missing outcome data across NCAs. Further
work by the respective methodology teams of NCAs is
required to assess if these findings are generalisable. The
heterogeneity of outcomes collected and differences in
the degree of missing data will likely lead to this proxy
having varying utility across different datasets.
Conclusion
For the first time, we have demonstrated that poor en-
gagement in a national audit program directly correlates
with the quality of care provided. Acknowledging meth-
odological limitations of this work, the key message is
unsurprising. Centre-level variation in care is frequently
overlooked in observational studies [22], yet any epi-
demiologist working in the field will recognise that
centre effects are large and significant. As research into
health care quality evolves, our data suggest that failing
to return outcome data is a viable service quality metric.
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